SCHEMBL19689482

SCHEMBL19689482

CC(C)(C)OC(=O)N1CC(O)(c2ccc(O[Si](C)(C)C(C)(C)C)cc2Cl)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.37
AXL P30530 1/20 0.37
CA12 O43570 3/20 0.37
CA1 P00915 3/20 0.37
CA9 Q16790 3/20 0.37
ESR2 Q92731 1/20 0.37
SCD5 Q86SK9 1/20 0.36
POLB P06746 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GPR183 P32249 1/20 0.35
PREP P48147 1/20 0.34
NR1H2 P55055 1/20 0.34
OXTR P30559 1/20 0.33
AVPR1A P37288 1/20 0.33
USP30 Q70CQ3 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
PDK2 Q15119 1/20 0.33
STS P08842 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29736070 1.00 MET (0.37) METAXLCA12CA1CA9
SCHEMBL22320341 0.88 CA12 (0.39) CA12CA1CA9PREP
SCHEMBL19202540 0.85 ALDH1A1 (0.43) METAXLESR2MEN1KMT2A
SCHEMBL31735017 0.82 RORC (0.42) ESR2POLBMEN1KMT2ANR1H2
SCHEMBL19689567 0.80 ESR2 (0.53) METAXLESR2POLBMEN1
SCHEMBL29735795 0.80 ESR2 (0.53) METAXLESR2POLBMEN1
SCHEMBL19698945 0.78 CA12 (0.38) CA12CA1CA9PREP
SCHEMBL19705736 0.77 ESR2 (0.38) METAXLESR2POLBMEN1
SCHEMBL30775155 0.77 CA12 (0.37) CA12CA1CA9PREP
SCHEMBL19689521 0.77 CA12 (0.37) CA12CA1CA9PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055094-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2026-02-26 US disclosed
EP-4691553-A2 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2026-02-11 EP disclosed
US-12358903-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2025-07-15 US disclosed
EP-4534536-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2025-04-09 EP disclosed
US-20250026744-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2025-01-23 US disclosed
EP-4089072-B1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2024-08-28 EP disclosed
EP-4360632-A2 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2024-05-01 EP disclosed
CN-117924266-A Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-04-26 CN disclosed
CN-117924267-A Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-04-26 CN disclosed
CN-109476636-B Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-01-09 CN disclosed
US-10329286-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2019-06-25 US disclosed
US-10329286-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2019-06-25 US disclosed
EP-3468962-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2019-04-17 EP disclosed
WO-2017218337-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed
WO-2017218337-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed
EP-3257847-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2017-12-20 EP disclosed
US-20170355685-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed
US-20170355693-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed
US-20170355693-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed
US-20170355693-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026744-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 MET 98/4885AXL 3314/4885CA12 4742/4885
US-12358903-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 MET 130/4885AXL 3396/4885CA12 4661/4885
US-10329286-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 MET 130/4885AXL 3396/4885CA12 4661/4885
US-20170355685-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 MET 130/4885AXL 3396/4885CA12 4661/4885
US-20260055094-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 MET 105/4885AXL 2497/4885CA12 4265/4885
US-20170355693-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 MET 130/4885AXL 3396/4885CA12 4661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.